Novartis launches 'next-generation' CAR-T platform
Novartis cancer CAR-T cell approval a boon for viral vector supplier
Uzm. Dr. Yaman Sağlam / Haberler / CAR T-Hücre Tedavisi Onkolojide Devrim Yaratıyor
Novartis Gains Access to Celyad's allogenic CAR-T cell patents
Novartis CAR-T cell therapy Kymriah gets EU approval for blood cancer | S&P Global Market Intelligence
The Science of CAR-T Cell Therapy | Novartis
Global Manufacturing of CAR T Cell Therapy: Molecular Therapy - Methods & Clinical Development
The Process of CAR-T Cell Therapy | Novartis
Novartis files CAR-T in lymphoma, sets up rivalry with Gilead | pharmaphorum
New Costly Cancer Treatments Face Hurdles Getting to Patients - WSJ
ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T meds | Fierce Pharma
CAR T-Cell Therapies Current Limitations Future Opportunities
Biotechs want in on Novartis' CAR-T platform
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Weighing the Cost and Value of CAR T-Cell Therapy - The ASCO Post
CAR-T Mechanism of Action | KYMRIAH® (tisagenlecleucel)
New way to safer CAR-T cell therapies - European Biotechnology
CAR-T: Novartis prices CTL019 at US$475,000 - European Biotechnology
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany | Gene Therapy
The Science of CAR-T Cell Therapy | Novartis
FDA Approves Pioneering Cancer Treatment With $475,000 Price Tag - WSJ
Novartis' CAR-T Kymriah scores SMC approval - PMLiVE
A guide to manufacturing CAR T cell therapies - ScienceDirect
